Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups.
Company's preliminary Q1 results reflect continued growth and raising 2026 Full Year Guidance.
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal.
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
The proposed transactions are subject to market conditions and other factors, and there can be no assurance as to whether or when these transactions may be completed, or as to the actual size or terms of the transactions.
